Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H2SPharm: Sulfhydryl-containing ACEi in Hypertension
NCT03179163Phase 2Terminated
- Sponsor
- The Pennsylvania State University
- Start
- Jul 2016
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of captopril in essential hypertension (4 arms), sponsored by The Pennsylvania State University. Primary endpoint: Change in Endothelium Dependent Vasodilation at 16 weeks. Started Jul 2016; status: terminated.
02
Drugs
captopril
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT03179163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179163.